Franziska Horling

Title: The Innovations of Franziska Horling

Introduction

Franziska Horling, an accomplished inventor based in Gaenserndorf, Austria, has made significant contributions to the field of gene therapy. With an impressive portfolio of 8 patents, her work specifically targets the treatment of hemophilia, a serious genetic disorder affecting blood clotting.

Latest Patents

Among her latest contributions are key patents that focus on gene therapy for hemophilia B and hemophilia A. Her patent on gene therapy of hemophilia B utilizes viral vectors encoding recombinant FIX variants with increased expression. This discovery includes codon-altered polynucleotides designed for expression in mammalian cells, which paves the way for innovative treatment methods. Similarly, her work on hemophilia A involves viral vectors encoding recombinant FVIII variants, also utilizing codon-altered polynucleotides for effective therapy.

Career Highlights

Franziska has built a remarkable career, contributing her expertise to significant companies in the biotechnology sector, such as Baxalta GmbH and Takeda Pharmaceutical Company Limited. Her research has focused on developing cutting-edge treatments that enhance the lives of those suffering from genetic disorders.

Collaborations

Throughout her career, Franziska has collaborated with esteemed colleagues, including Johannes Lengler and Hanspeter Rottensteiner. These partnerships have helped advance her research in gene therapy and have been instrumental in her patent applications.

Conclusion

Franziska Horling's innovations in the field of gene therapy exemplify the vital role inventors play in the advancement of medical science. Through her patents and collaborations, she continues to make strides toward improving treatment options for patients with hemophilia, showcasing the impact of innovative thinking in healthcare.